Generics Global Group of Eight (G8) Industry Guide - Market Summary, Competitive Analysis and Forecast to 2025


Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.


Key Highlights

  • The G8 countries contributed $198,022.1 million in 2020 to the global generics industry, with a compound annual growth rate (CAGR) of 3.7% between 2016 and 2020. The G8 countries are expected to reach a value of $229,134.5 million in 2025, with a CAGR of 3% over the 2020-25 period.
  • Among the G8 nations, the US is the leading country in the generics industry, with market revenues of $110,220.5 million in 2020. This was followed by Japan and Germany, with a value of $28,640.0 and $25,180.5 million, respectively.
  • The US is expected to lead the generics industry in the G8 nations with a value of $124,141.2 million in 2016, followed by Japan and Germany with expected values of $32,238.2 and $28,441.8 million, respectively.




Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
  • Leading company profiles reveal details of key generics market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country




Reasons To Buy

  • What was the size of the G8 generics market by value in 2020?
  • What will be the size of the G8 generics market in 2025?
  • What factors are affecting the strength of competition in the G8 generics market?
  • How has the market performed over the last five years?
  • How large is the G8 generics market in relation to its regional counterparts?